Cost-effectiveness of lumbar discectomy and single-level fusion for spondylolisthesis: experience with the NeuroPoint-SD registry

PRAVEEN V. MUMMANENI, M.D.,1 ROBERT G. WHITMORE, M.D.,2,3 JILL N. CURRAN, M.S.,2,3 JOHN E. ZIEWACZ, M.D., M.P.H.,4 RISHI WADHWA, M.D.,1 CHRISTOPHER I. SHAFFREY, M.D.,5 ANTHONY L. ASHER, M.D.,6 ROBERT F. HEARY, M.D.,7 JOSEPH S. CHENG, M.D.,8 R. JOHN HURLBERT, M.D., Ph.D.,6 ANDREA F. DOUGLAS, M.D.,7 JUSTIN S. SMITH, M.D., Ph.D.,5 NEIL R. MALHOTRA, M.D.,6 STEPHEN J. DANTE, M.D.,4 SUBU N. MAGGE, M.D.,2 MICHAEL G. KAISER, M.D.,10 KHALID M. ABBED, M.D.,1 DANIEL K. RESNICK, M.D.,12 AND ZOHDER GHOGAWALA, M.D.2,3

1Department of Neurological Surgery, University of California, San Francisco, California; 2Alan and Jacqueline Stuart Spine Research Center, Department of Neurosurgery, Lahey Hospital and Medical Center, Burlington, Massachusetts; 3Wallace Trials Center, Greenwich Hospital, Greenwich, Connecticut; 4Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania; 5Department of Neurosurgery, University of Virginia, Charlottesville, Virginia; 6Carolina Neurosurgery & Spine, Charlotte, North Carolina; 7Rutgers New Jersey Medical School, Newark, New Jersey; 8Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee; 9Department of Clinical Neurosciences, University of Calgary Spine Program, Calgary, Alberta, Canada; 10Department of Neurosurgery, Columbia University, New York, New York; 11Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut; and 12Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Object. There is significant practice variation and uncertainty as to the value of surgical treatments for lumbar spine disorders. The authors’ aim was to establish a multicenter registry to assess the efficacy and costs of common lumbar spinal procedures by using prospectively collected outcomes.

Methods. An observational prospective cohort study was completed at 13 academic and community sites. Patients undergoing single-level fusion for spondylolisthesis or single-level lumbar discectomy were included. The 36-item Short Form Health Survey (SF-36) and Oswestry Disability Index (ODI) data were obtained preoperatively and at 1, 3, 6, and 12 months postoperatively. Power analysis estimated a sample size of 160 patients: lumbar disc (125 patients) and lumbar listhesis (35 patients). The quality-adjusted life year (QALY) data were calculated using 6-dimension utility index scores. Direct costs and complication costs were estimated using Medicare reimbursement values from 2011, and indirect costs were estimated using the human capital approach with the 2011 US national wage index. Total costs equaled $14,980 for lumbar discectomy and $43,852 for surgery for lumbar spondylolisthesis.

Results. There were 198 patients enrolled over 1 year. The mean age was 46 years (49% female) for lumbar discectomy (n = 148) and 58.1 years (60% female) for lumbar spondylolisthesis (n = 50). Ten patients with disc herniation (6.8%) and 1 with listhesis (2%) required repeat operation at 1 year. The overall 1-year follow-up rate was 88%. At 30 days, both lumbar discectomy and single-level fusion procedures were associated with significant improvements in ODI, visual analog scale, and SF-36 scores (p = 0.0002), which persisted at the 1-year evaluation (p < 0.0001). By 1 year, more than 80% of patients in each cohort who were working preoperatively had returned to work. Lumbar discectomy was associated with a gain of 0.225 QALYs over the 1-year study period ($66,578/QALY gained). Lumbar spinal fusion for Grade I listhesis was associated with a gain of 0.195 QALYs over the 1-year study period ($224,420/QALY gained).

Conclusions. This national spine registry demonstrated successful collection of high-quality outcomes data for spinal procedures in actual practice. These data are useful for demonstrating return to work and cost-effectiveness following surgical treatment of single-level lumbar disc herniation or spondylolisthesis. One-year cost per QALY was obtained, and this cost per QALY is expected to increase further by 2 years. This work sets the stage for real-world analysis of the value of health interventions.

(http://thejns.org/doi/abs/10.3171/2014.3.FOCUS1450)

Key Words • discectomy • fusion • outcome • spondylolisthesis • cost • quality-adjusted life year

Abbreviations used in this paper: CPT = current procedural terminology; DRG = diagnosis-related group; HIPAA = Health Insurance Portability and Accountability Act; HRQOL = health-related quality of life; NeuroPoint-SD = NeuroPoint–Spinal Disorders; NPA = NeuroPoint Alliance; ODI = Oswestry Disability Index; QALY = quality-adjusted life year; RCT = randomized controlled trial; SF-6D = 6-dimension utility index; SF-12 and SF-36 = 12- and 36-Item Short Form Health Survey; SPORT = Spine Patient Outcomes Research Trial.

With implementation of the Patient Protection and Affordable Care Act set for 2014, there is increased interest in medical resource allocation and an emphasis on determining the value of health interventions. One of the primary areas of importance for researchers and policymakers is the cost burden of lumbar spine disorders for US society. The economic impact of lumbar spine disorders is now estimated to exceed...
$100 billion per year and is nearly equal to the costs associated with treating all types of cancer. Although there is extensive literature on patient outcomes and costs following lumbar spinal surgery, there are very few Level 1 studies available to influence practice patterns. The Spine Patient Outcomes Research Trial (SPORT) data for lumbar disc herniation, spinal stenosis, and degenerative spondylolisthesis have in part suggested that the heterogeneity of lumbar spine disorders and patient preferences for treatment demonstrate that randomized controlled trial (RCT) methodology is difficult or impossible to apply to this population.

A prospective, nonrandomized registry has the advantage of being able to collect high-quality, prospective data with validated outcome tools that may more closely represent actual practice conditions than an RCT. Therefore, real clinical effectiveness data may be derived from registry studies. The aim of this registry study (NeuroPoint–Spinal Disorders [NeuroPoint-SD]) was to create an alliance of tertiary and community-based spine surgeons with a simple web-based infrastructure to collect outcomes data for common lumbar spinal procedures. NeuroPoint-SD demonstrated clinical effectiveness for 2 common lower back surgical procedures: lumbar discectomy and lumbar spinal fusion for spondylolisthesis. At 30 days, lumbar discectomy and single-level fusion procedures were associated with significant improvements in Oswestry Disability Index (ODI), visual analog scale, and 36-Item Short Form Health Survey (SF-36) scores that persisted over the 1-year follow-up period.

The purpose of this analysis was to determine the cost-effectiveness from a societal perspective of lumbar discectomy and single-level lumbar fusion by using the prospective data collected from NeuroPoint-SD. The calculated cost per quality-adjusted life year (QALY) gained is placed into context by comparing it to the societal willingness-to-pay threshold as well as to other common operations such as total knee and hip replacement.

Methods

Study Design

A prospective, observational cohort registry study enrolled patients from 13 sites over a 1-year period and collected data from unselected patients undergoing lumbar discectomy or single-level fusion for spondylolisthesis. Outcomes were measured and observed over a 1-year period postoperatively.

Data Coordination

Institutional review board approval of the clinical protocol was obtained and research contracts were executed for this prospective registry at 13 academic and community sites nationwide in September 2010. Patient data were managed at the central coordinating center (Wallace Clinical Trials Center). All patient data were de-identified before transfer from each treating institution to protect patient confidentiality, in compliance with the Health Insurance Portability and Accountability Act (HIPAA). All patient data were entered into a secure, HIPAA-compliant, internet-based data management platform, the NeuroPoint Alliance (NPA), which was developed by Outcome Sciences in conjunction with the American Association of Neurological Surgeons. Enrollment occurred over a 1-year period (September 2010–September 2011).

Data Sources and Measurement

All questionnaires were administered in the outpatient office setting unless the subject was not seen in the specifically required timeframe. In this situation, the subject was mailed the questionnaires to complete and return to the study site coordinator. Subjects completing the questionnaires at home were instructed to call study site coordinators with any questions. In addition, site coordinators reviewed questionnaires for completeness. Subjects were contacted via phone to assess work status, to document any complications during the study period, and to address and complete any missing data from the questionnaires. Each patient who failed to return follow-up questionnaires was contacted 3 times via mail and/or phone call to ensure maximal patient compliance.

Study Population

Patients 18–80 years of age who had either symptomatic lumbar disc herniation (Fig. 1) that was recalcitrant to noninvasive therapies for at least 6 weeks, or symptomatic lumbar degenerative spondylolisthesis (Fig. 2)—with or without radiculopathy—that was recalcitrant to noninvasive therapies for at least 3 months were eligible. Patients were excluded for any of the following reasons: 1) history of previous lumbar spinal surgery at the level of disc herniation or spondylolisthesis; 2) significant motor weakness on manual muscle testing of 3/5 or less (that is, foot drop) or cauda equina syndrome; 3) cancer, infection, or fracture involving any portion of the spine; and 4) pregnancy. Each site was permitted to enroll up to 25 unselected patients within the 1-year study period.

Patients were recruited from 13 sites without regard to sex, race, age, language preference, or socioeconomic status. There was no specific advertising to recruit patients, although the clinical registry was listed with www.clinicaltrials.gov and on most of the participating institution’s clinical research web pages. All potentially eligible patients were screened by a study coordinator for potential enrollment. All patients who were eligible and who agreed to participate were asked to sign an institutional review board–approved consent form to participate in the study. The patient’s treatment was not affected in any way for choosing not to participate in the study.

Outcomes Assessment

The primary end point of this study was the physical function domain from the general health-related quality of life (HRQOL) measure—the RAND Medical Outcomes Study SF-36. It was expected that all sites would have at least an 80% compliance rate for the completion of all outcomes questionnaires during the 1-year study period.

Patients completed one disease-specific outcome measure, the ODI, one general HRQOL measure, and the norm-based SF-36 preoperatively and 1, 3, 6, and 12 months postoperatively. Return to work and complication
assessments were completed by an independent study coordinator at each site. Complications included all major adverse events (death, myocardial infarction, pulmonary embolus, infection, CSF leakage, new neurological deficit [for example, foot drop], readmission, and repeat operation). Delayed complications (repeat operation, fusion complications, problems with instrumentation, deformity) were recorded at 1 year.

Surgical Treatment

All patients underwent surgery at the discretion of the surgeon and the patient. Lumbar discectomy was performed as described. Decompression and instrumented pedicle screw lumbar spinal fixation and fusion, with or without interbody device placement, were performed in all patients with isthmic or degenerative lumbar spondylolisthesis.

Study Sample Size Estimates

Based on the published data for the patients with lumbar discectomy from the SPORT studies, we assumed a preoperative value of 30 for SF-36 physical function (standard deviation between 23 and 25), with treatment effect from 40 to 45 points. On 2-sided t-tests, at a 5% significance level, we calculated that a sample size of 10 patients per site would be necessary to demonstrate the effectiveness of lumbar discectomy at 80% power, leading to the total sample size estimate for the lumbar discectomy cohort of 100 patients. The sample size was inflated to 125 patients to accommodate attrition during the follow-up.

Based on the published data for the spondylolisthesis patients from the SPORT study, we assumed a preoperative value of 40 for SF-36 physical function (standard deviation between 20 and 24), with a treatment effect of 30 points. On 2-sided t-tests, at a 5% significance level, we calculated that a sample size of 25 patients would be necessary to demonstrate the effectiveness of the procedure for the spondylolisthesis cohort at 80% power. The sample size was inflated to 35 patients to accommodate attrition during the follow-up.

The total sample size estimate for statistical power was 160 patients [125 (lumbar discectomy) + 35 (lumbar spondylolisthesis)]. Based on the unpredictability of enrollment from individual sites, we increased the number of sites from 10 to 13. Total enrollment was targeted at 200 unselected patients over a 1-year period. Sample size calculations were not specifically performed for the economic analysis or collection of cost data.

Statistical Analysis

A p value of < 0.05 was considered statistically significant. Analyses were performed using Stata 12.1. To conduct a cost-effectiveness analysis, we first calculated utility gained at 1 year by converting SF-36 data to 6-dimensional utility index (SF-6D) values by using ordinal and standard gamble health-state valuation models. The QALYs were determined by the change in utility between baseline and 1 year, multiplied by the duration of time in years (1 year in this study). Direct costs from a societal
perspective for lumbar discectomy and single-level fusion were estimated using 2011 Medicare reimbursement values for current procedural terminology (CPT) codes and diagnosis-related group (DRG) codes (Table 1) (http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx).6,7,36 Indirect costs were estimated using the human capital method; that is, the amount of missed work multiplied by the US national wage index from 2011 (http://www.ssa.gov/oact/cola/AWI1.html).17 The cost of complications from lumbar discectomy and lumbar fusion was included if the complication resulted in a reoperation. In this instance, the direct cost of the complication was estimated from Medicare reimbursement values as described above. Direct costs did not include out-of-pocket or outpatient expenses, or costs derived from radiology, medicines, or physical devices associated with lumbar spinal surgery, although these costs are often accrued in the nonsurgical group as well.

Only patients who had both QALY and cost data were used for the cost analysis. To deal with missing data, both the mean imputation and last observation carried forward were used. Specifically, for patients missing return to work data, the average number of missed work days for each cohort (lumbar discectomy and lumbar fusion) were imputed and used to estimate indirect costs. For patients missing 1-year QALY data, the last observation carried forward was used for patients who had 6-month QALY data. Patients who did not have 6-month or 1-year QALY data were not included in the cost analysis. The final cost analysis included 172 patients; 126 lumbar discectomy and 46 lumbar fusion patients.

Total societal costs were estimated as direct costs plus indirect costs plus complication costs. The acceptable cost per additional QALY is a societal determination and serves as a foundation for cost-effectiveness analyses. Confidence intervals for the cost per QALY estimate were calculated using the nonparametric bootstrap method (http://www.stata.com/features/overview/bootstrap-sampling-and-estimation/). The most recent literature cites $100,000/QALY gained as the threshold for a cost-effective intervention.2,20

**TABLE 1: Medicare reimbursement rates in 2011 for lumbar discectomy and lumbar fusion**

<table>
<thead>
<tr>
<th>Op</th>
<th>CPT Code(s)</th>
<th>2011 Medicare Reimbursement</th>
<th>DRG Code*</th>
<th>2011 Medicare Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>lumbar discectomy</td>
<td>63030</td>
<td>$961.53</td>
<td>491</td>
<td>$5536.22</td>
</tr>
<tr>
<td>lumbar fusion</td>
<td>22630</td>
<td>$1535.73</td>
<td>460</td>
<td>$21,617.69</td>
</tr>
<tr>
<td></td>
<td>22842</td>
<td>$779.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>63047</td>
<td>$1095.06</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The DRG codes were selected assuming patients did not have major comorbidities.

P. V. Mummaneni et al.

**Results**

**Patient Population**

A total of 211 patients were screened and 198 were enrolled from 13 academic and community sites (mean 15 patients/site) over 1 year. The mean age was 46 years and median body mass index 27.3 kg/m² (49% female, 2% with diabetes, and 21% smokers) for lumbar discectomy (n = 148); and the mean age was 58.1 years and median body mass index 30 kg/m² (60% female, 8% with diabetes, and 10% smokers) for lumbar spondylolisthesis (n = 50) (Table 2).

**Compliance and Database Auditing**

Overall, there was 88.3% compliance (site range 25%–97.3%) with patient-reported outcomes data collection. The average period of enrollment at each site was 7.5 months. Target enrollment was capped at a maximum of 25 patients per site. Baseline evaluations were completed in 100% of patients. Outcomes assessment compliance (follow-up) was 87.4%, 86.9%, and 83.3% at 3, 6, and 12 months, respectively. At 1 year, there was 83.3% compliance in completing an independent complications assessment.

**Outcome Assessments**

At 30 days, lumbar discectomy and single-level fusion procedures were associated with significant improvements in SF-36 scores (p = 0.0002), which persisted over the 1-year follow-up. The SF-36 scores were converted to SF-6D scores to calculate QALYs gained.3 Lumbar discectomy was associated with a gain of 0.225 QALYs, and lumbar spinal fusion for Grade I spondylolisthesis was associated with a gain of 0.195 QALYs over the 1-year study period (Fig. 3).

**Postoperative Complications**

At 30 days, 12 complications (6.1% of study population) were identified. Complications in the discectomy cohort included 4 wound infections, 2 new postoperative neurological deficits, and 4 reoperations at the surgically treated level. Complications in the spondylolisthesis cohort included 1 symptomatic CSF leak requiring reoperation within 30 days and 1 aortic occlusion with nonfatal cardiac arrest. By 1-year follow-up, a total of 10 patients with disc herniation (6.8%) and 1 with spondylolisthesis (2%) required reoperations at the index level. One patient (2%) in the spondylolisthesis cohort had a complication resulting from the instrumentation.

**Return to Work**

A total of 105 patients with disc herniation (70.9%) and 24 with spondylolisthesis (48%) were working preoperatively. By 1-year follow-up, more than 80% of the patients in each cohort who were working preoperatively had returned to work. The average time of missed work was 67 days (± 86 days [SD]) for lumbar discectomy patients and 156 days (± 130 days [SD]) for lumbar fusion patients. The economic cost associated with missed work following lumbar discectomy and for lumbar fusion is shown in Fig. 4.
Economic Analysis

Total costs for lumbar discectomy are $14,980 (Table 3). The direct cost for reoperation for lumbar discectomy was estimated as $6498 from 2011 Medicare reimbursement values. The average cost of complications for lumbar discectomy was $464, including all reoperations. The calculated cost per QALY for lumbar discectomy is $66,578 (95% CI $55,858–$77,439). Total costs for single-level lumbar fusion are $43,852 (Fig. 5). The direct cost of reoperation for lumbar fusion was estimated as $25,028. The average cost of complications for lumbar fusion was $544, including all reoperations. The cost per QALY for single-level lumbar spinal fusion is $224,420 (95% CI $170,686–$278,154) at the 1-year time point.

Discussion

NeuroPoint-SD represents the first multicenter prospective registry to demonstrate clinical effectiveness for lumbar discectomy and single-level lumbar fusion at 1 year. Fusion for Grade I spondylolisthesis is not cost-effective at 1 year, but the gain in QALYs associated with lumbar fusion suggests that it will become cost-effective over a 2-year period. Unfortunately, we will not be able to verify this with our own data due to the restricted time frame of 1 year in our pilot project database. It is relevant to note that in the SPORT study, the observed improvement following a single-level lumbar fusion was durable for more than 2 years. If the observed improvements in the NeuroPoint-SD cohort are durable for at least 2–4 years as observed in the SPORT study, then the cost per QALY will drop significantly.

The NeuroPoint-SD registry has created infrastructure to prospectively measure outcomes and costs of all common spinal procedures. The difficulties faced in previous trials related to the heterogeneity of patients with spine disorders and to the surgeries performed will be mitigated by the larger sample size, real practice conditions, and prolonged follow-up. In the upcoming era of quality improvement and cost containment, spine registries will need to be capable of monitoring not only the complications from procedures but their costs as well.

It is important to highlight that although some of the existing data on QALY comes from RCTs, the RCTs may not represent the real world, and the cost of an RCT may hinder the sustainability of such studies. The authors in this study have evaluated real-world populations from a diverse group of institutions engaged in day-to-day surgical care. By the nature of the database, not only is it sustainable, but it also could provide a realistic means to accurately track QALY over time rather than in unique situations.

Cost per QALY Comparisons

The results of this analysis are consistent with the existing literature for lumbar spinal surgery. Tosteson et al. reported that surgery, including fusion, for degenerative
spondylolisthesis was associated with a gain in QALYs of 0.23 at a cost of $115,600 over a 2-year period.33 Similarly, lumbar discectomy was associated with a gain of 0.21 QALYs at a cost of $34,355 over a 2-year period.34 The durable gains in outcome at 1 year in this study are likely to persist based on prior literature, causing the value of operative intervention for lumbar discectomy and lumbar fusion to improve over time.35 At 4-year follow-up, the cost per QALY for surgery to treat degenerative spondylolisthesis decreased from $115,600 to $64,300.35

There is extensive orthopedic literature on the cost-effectiveness of total joint replacement that can be referenced for comparative purposes. A recent review reported that total hip arthroplasty is associated with a cost per QALY gained of $10,402 in 2011 $US for the duration of a patient’s life, and total knee arthroplasty ranges from $13,000/QALY over a 5-year time period to $22,000/QALY for the duration of a patient’s life.10 The addition of computer navigation to improve limb and arthroplasty component alignment for total knee arthroplasty increases the cost per QALY to $54,234 over a 15-year period, but improves precision of the implant by 14%.11 In addition, patients at higher risk for surgery due to comorbidities who underwent total knee arthroplasty were associated with a significantly higher cost per QALY of $135,700.21

Although these studies report cost per QALY values for total joint arthroplasty that are more cost-effective than those for lumbar discectomy and lumbar fusion reported in this study, the time period of outcome measurement is also significantly longer. Polly et al. directly compared the cost/benefit ratio of lumbar fusion to total joint arthroplasty and coronary artery bypass surgery by using data from several randomized clinical trials.26 Lumbar fusion had a lower cost per outcome (SF-36) improvement than coronary artery bypass surgery, equivalent to total knee arthroplasty, and slightly higher cost per outcome improvement compared with total knee arthroplasty at 1 and 2 years following surgery.

Several studies have compared the outcomes following joint arthroplasty to surgery for lumbar spine disorders. Rampersaud et al. performed a direct comparison of the outcomes following surgery for focal lumbar spinal stenosis, total hip arthroplasty, and total knee arthroplasty at 1-year and 2-year follow-up.27 A subgroup analysis of patients who received lumbar fusion (with or without spondylolisthesis) showed that they attained improvement in HRQOL scores equal to total hip arthroplasty. Similar results were demonstrated by a follow-up multicenter prospective trial conducted by the same group.28 Mokhtar et al. reported equivalent improvement by SF-12 at 2 years for patients who underwent surgery for lumbar spondylolisthesis compared with total hip arthroplasty, and superior improvements compared with total knee arthroplasty.24 The gain in QALYs was reported to be between 0.3 and 0.4 for total hip arthroplasty and between 0.15 and 0.3 for total knee arthroplasty.9,21 The gain in QALYs following surgical intervention is highly variable, depending on patient-specific factors such as the type of arthritis prompting arthroplasty. For patients with inflammatory arthropathies such as rheumatoid arthritis, the gain in QALY at 1 year after total joint arthroplasty is reported to be very small: 0.10 using EQ-5D and 0.03 with SF-6D.25

These orthopedic large-joint replacement studies serve as important comparisons for this analysis. The outcomes and costs following surgery are highly dependent on patient selection. Although the NeuroPoint-SD registry has some limited exclusion criteria, the majority of patients with lumbar spine disorders, including those with rheumatoid arthritis, are included and combined with patients with simple degenerative arthritis. This pilot eco-

---

**TABLE 3: Costs of lumbar discectomy and lumbar fusion**

<table>
<thead>
<tr>
<th></th>
<th>Op Direct Cost</th>
<th>Indirect Cost</th>
<th>Complication Cost</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>lumbar discectomy</td>
<td>$6498</td>
<td>$8018</td>
<td>$464</td>
<td>$14,980</td>
</tr>
<tr>
<td>lumbar fusion</td>
<td>$25,028</td>
<td>$18,280</td>
<td>$544</td>
<td>$43,852</td>
</tr>
</tbody>
</table>

* All costs represent the average.

---

**Fig. 5.** Bar graph showing direct, indirect, and complication costs of lumbar discectomy and lumbar fusion.
Cost-effectiveness of lumbar discectomy and fusion.

Nomic analysis has demonstrated that lumbar discectomy is cost-effective, despite the increased heterogeneity of the patient population captured in the actual practice conditions of this registry. With longer follow-up and larger sample size, the true value of surgeries for lumbar spine disorders may be determined.

Limitations of the Study

There are several limitations with this study. In its initial phase, NeuroPoint-SD did not collect cost data in a prospective fashion. Therefore, all cost data reported in this study are estimates, based on 2011 Medicare reimbursement values and with CPT and DRG code assumptions. The cost data do not include out-of-pocket, outpatient, medication, device, radiological, or anesthesia expenses. The true societal cost of these procedures is likely to be higher, particularly when these additional variables are included.

The gain in QALY reported in this paper may be inaccurate because we assume that all changes in utility are the result of surgery. In reality, many other factors such as patient bias toward surgery, participation in conservative therapies, and the passage of time may contribute to changes in QALY. An incremental cost-effectiveness ratio could not be calculated for this analysis because outcomes and costs of nonoperative treatments for lumbar discectomy and lumbar fusion were not recorded. Calculation of the incremental cost-effectiveness ratio is currently the gold standard of cost-effectiveness analysis as it pertains to surgical intervention.

This cost analysis is also limited by the small sample size. Indirect costs were highly variable (Table 3) in this study population and represented a substantial percentage of the total costs. There were several outlier patients who may have skewed the results of indirect costs, such as a patient who underwent lumbar discectomy and missed more than 400 days of work. It is unclear if these patients had some secondary incentive to miss work such as receiving worker’s compensation or disability.

Conclusions

The NeuroPoint-SD registry has demonstrated clinical effectiveness of lumbar discectomy and single-level lumbar fusion for Grade I lumbar spondylolisthesis at 1 year. Lumbar discectomy is cost-effective at 1 year, assuming a $100,000/QALY gained societal willingness-to-pay threshold. In the short-term follow-up, lumbar fusion is not cost-effective; however, reported long-term follow-up for patients with lumbar spinal fusion has demonstrated the cost-effectiveness of many of these procedures. Spine registries represent a unique opportunity. This lumbar spine registry has set the stage for a much larger initiative to collect outcomes and cost data on heterogeneous patient populations involving multiple institutions.

Acknowledgment

The work was coordinated by the NPA.

Disclosure

Funding was provided by the AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves, the AANS, and the Jean and David Wallace Foundation (GH382). Dr. Heary receives royalties from DePuy Synthes Spine, Zimmer Spine, and Thieme Medical Publishers. Dr. Malhotra is a consultant for Stryker. Dr. Mummaneni receives royalties and honoraria from DePuy Spine, honoraria from Globus, royalties from Thieme Medical Publishers, and royalties from Quality Medical Publishing. He owns stock in Spincity. Dr. Smith is a consultant for Biomet, Globus, Medtronic, and DePuy, and he receives support from ISSGFi/DePuy for a non-study-related clinical or research effort that he oversees. Dr. Ghogawala received clinical and research support for this study from the Wallace Foundation. Dr. Shaffrey is a consultant for Biomet, Globus, Medtronic, NuVasive, and Stryker. He has patents with and receives royalties from Biomet and Medtronic.


References

12. Fairbank JC, Couper J, Davies JB, O’Brien JP: The Oswes...

P. V. Mummaneni et al.